英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
nekro查看　nekro　在百度字典中的解释百度英翻中〔查看〕
nekro查看　nekro　在Google字典中的解释Google英翻中〔查看〕
nekro查看　nekro　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Understanding immune checkpoints and PD-1 PD-L1-mediated . . .
    Abstract Immunotherapy has emerged as a transformative approach in the treatment of various cancers, offering new hope for patients previously faced with limited treatment options A cornerstone of cancer immunotherapy lies in targeting immune checkpoints, particularly the programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway Immune checkpoints serve as crucial
  • Immune Checkpoint Inhibitors - NCI - National Cancer Institute
    Immune checkpoint inhibitors are a type of immunotherapy that block immune checkpoint proteins from binding with partner proteins Learn about the cancers treated with checkpoint inhibitors and the side effects they may cause
  • PD-1 and PD-L1 inhibitors - Wikipedia
    The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001 [6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first clinical trial was launched in 2006, evaluating nivolumab As of 2017, more than 500 clinical trials involving PD-1 and PD-L1 inhibitors have been conducted in more than 20,000 patients [7] By the
  • Immune Checkpoint Inhibitors and Their Side Effects
    Immune checkpoint inhibitors, like PD-1 or PD-L1 inhibitors, are treatments that help the immune system recognize and attack cancer cells Learn more here
  • Understanding PD-1 and PD-L1 in Cancer Immunotherapy
    Understanding the role of PD-1 and PD-L1 in cancer is essential to comprehend current immunotherapy strategies PD-1, a checkpoint protein on T-cells, and PD-L1, its ligand found on tumor cells, have significant implications for immune response regulation
  • Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity . . .
    Most cancer patients respond transiently to immunotherapy, highlighting the importance of understanding the mechanisms underlying resistance Tichet et al reveal that the immunocytokine PD1-IL2v combined with anti-PD-L1 synergize to enable anti-tumor immunity against immunotherapy-resistant tumors PD1-IL2v promotes stem-like, tumor-reactive CD8+ T cell expansion and high endothelial venule
  • Use of PD-1 vs PD-L1 Inhibitors in Patients With Cancer
    This systematic review and meta-analysis of randomized clinical trials examines use of programmed cell death 1 (PD-1) vs programmed cell death–ligand 1 (PD-L1) treatment in patients with cancer
  • Assessing the Pharmacological and Pharmacogenomic Data of PD . . .
    Background Objectives: Advances in understanding immune checkpoint pathways and tumor immune biology have enabled the development of immune checkpoint inhibitors (ICIs), particularly targeting the PD-1 PD-L1 axis, which has transformed cancer immunotherapy While they have shown remarkable success in various cancer types, including melanoma, non-small cell lung cancer, and gastrointestinal
  • Next generation approaches in cancer immunotherapy targeting . . .
    Abstract Cancer immunotherapy has revolutionized oncology by leveraging the immune system’s ability to recognize and eliminate tumor cells Among the most impactful advances are immune checkpoint inhibitors that target the programmed death-1 (PD-1) receptor and its ligand PD-L1, which can restore T cell activity and generate durable responses across several cancer types However, their





中文字典-英文字典  2005-2009